1. Home
  2. NMRA vs GECC Comparison

NMRA vs GECC Comparison

Compare NMRA & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • GECC
  • Stock Information
  • Founded
  • NMRA 2019
  • GECC 2016
  • Country
  • NMRA United States
  • GECC United States
  • Employees
  • NMRA N/A
  • GECC N/A
  • Industry
  • NMRA
  • GECC Finance: Consumer Services
  • Sector
  • NMRA
  • GECC Finance
  • Exchange
  • NMRA Nasdaq
  • GECC Nasdaq
  • Market Cap
  • NMRA 121.0M
  • GECC 122.4M
  • IPO Year
  • NMRA 2023
  • GECC N/A
  • Fundamental
  • Price
  • NMRA $0.84
  • GECC $10.80
  • Analyst Decision
  • NMRA Buy
  • GECC
  • Analyst Count
  • NMRA 8
  • GECC 0
  • Target Price
  • NMRA $9.29
  • GECC N/A
  • AVG Volume (30 Days)
  • NMRA 1.4M
  • GECC 24.8K
  • Earning Date
  • NMRA 08-05-2025
  • GECC 07-31-2025
  • Dividend Yield
  • NMRA N/A
  • GECC 14.00%
  • EPS Growth
  • NMRA N/A
  • GECC N/A
  • EPS
  • NMRA N/A
  • GECC 0.42
  • Revenue
  • NMRA N/A
  • GECC $42,909,000.00
  • Revenue This Year
  • NMRA N/A
  • GECC $32.54
  • Revenue Next Year
  • NMRA N/A
  • GECC N/A
  • P/E Ratio
  • NMRA N/A
  • GECC $25.87
  • Revenue Growth
  • NMRA N/A
  • GECC 18.13
  • 52 Week Low
  • NMRA $0.61
  • GECC $8.87
  • 52 Week High
  • NMRA $17.19
  • GECC $11.39
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 52.19
  • GECC 57.57
  • Support Level
  • NMRA $0.72
  • GECC $10.28
  • Resistance Level
  • NMRA $0.85
  • GECC $10.60
  • Average True Range (ATR)
  • NMRA 0.07
  • GECC 0.25
  • MACD
  • NMRA -0.01
  • GECC 0.03
  • Stochastic Oscillator
  • NMRA 62.35
  • GECC 80.33

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.

Share on Social Networks: